Press releases

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...

Hervé Brailly, co-founder and executive of Innate Pharma SA [IPH], one of the world's leading immuno-oncology specialists and one of the...

Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...

Completion of the contribution in kind of DEINOBIOTICS’ shares to DEINOVE which now holds 100% of its subsidiary Consequential DEINOVE’s...

Cash position: +€10.4 M at June 30, 2016 compared to +€12.4 M at December 31, 2015 Stability of interim net loss at -€3.1M Strategic...